Who are Escalation Therapies Group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ibritumomab Tiuxetan (Zevalin), LI, HAART + Immunotherapy, Zopapogene imadenovec (Zopa), Diphtheria Antitoxin, Routine continuous cluster of Alutard SQ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/escalation-therapies-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Escalation Therapies Group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Escalation Therapies Group (Escalation Therapies Group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy. Area: Oncology.

marketed Immunotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Escalation Therapies Group (Escalation Therapies Group) — The Cleveland Clinic. Escalation Therapies Group involves gradually increasing the intensity of a treatment to achieve a desired therapeutic effect.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Escalation Therapies Group TARGET	Escalation Therapies Group	The Cleveland Clinic	marketed	Immunotherapy
Ibritumomab Tiuxetan (Zevalin)	Ibritumomab Tiuxetan (Zevalin)	M.D. Anderson Cancer Center	marketed	Radioimmunotherapy agent; anti-CD20 monoclonal antibody	CD20
LI	LI	CEL-SCI Corporation	marketed	Cancer immunotherapy vaccine
HAART + Immunotherapy	HAART + Immunotherapy	Juan A. Arnaiz	marketed	Combination antiretroviral + immunotherapy
Zopapogene imadenovec (Zopa)	Zopapogene imadenovec (Zopa)	Precigen, Inc	marketed	Oncolytic immunotherapy	Tumor cells (non-selective replication); immunostimulatory transgene product
Diphtheria Antitoxin	Diphtheria Antitoxin	PT Bio Farma	marketed	Antitoxin (passive immunotherapy)	Diphtheria toxin
Routine continuous cluster of Alutard SQ	Routine continuous cluster of Alutard SQ	Beijing Tongren Hospital	marketed	Allergen immunotherapy (subcutaneous immunotherapy, SCIT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
CytoVac A/S · 1 drug in this class
Hannover Medical School · 1 drug in this class
Pfizer · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
Zarour, Hassane, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Escalation Therapies Group — Competitive Intelligence Brief. https://druglandscape.com/ci/escalation-therapies-group. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab